ES2121603T3 - Derivados de 10,11-metanodibenzosuberano usados como agentes quimiosensibilizantes. - Google Patents

Derivados de 10,11-metanodibenzosuberano usados como agentes quimiosensibilizantes.

Info

Publication number
ES2121603T3
ES2121603T3 ES94914200T ES94914200T ES2121603T3 ES 2121603 T3 ES2121603 T3 ES 2121603T3 ES 94914200 T ES94914200 T ES 94914200T ES 94914200 T ES94914200 T ES 94914200T ES 2121603 T3 ES2121603 T3 ES 2121603T3
Authority
ES
Spain
Prior art keywords
sub
sup
methanodibenzosuberano
derivatives
chr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94914200T
Other languages
English (en)
Inventor
Jurg Roland Pfister
Doris Lynne Slate
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2121603T3 publication Critical patent/ES2121603T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

LOS DERIVADOS DE 10,11-METANODIBENZOSUBERANO, A SABER, LOS COMPUESTOS DE LA FORMULA (I), EN LA QUE A ES -CH{SUB,2}CH{SUB,2}-, CH{SUB,2}-CHR{SUP,A}-CH{SUB,2}- O -CH{SUB,2}CHR{SUP,A}-CHR{SUP,B}-CH{SUB,2}-, DONDE UNO DE ENTRE R{SUP,A} O R{SUP,B} ES H, OH, O ACILOXI INFERIOR, Y EL OTRO ES HIDROGENO; R{SUP,1} ES H, F, CL O BR; R{SUP,2} ES H, F, CL O BR; Y R{SUP,3} ES HETEROARILO O FENILO OPCIONALMENTE SUSTITUIDO POR F, CL, BR, CF{SUB,3}, CN, NO{SUB,2} U OCHF{SUB,2}; Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, SON AGENTES QUIMIOSENSIBILIZADORES UTILES, EJ., PARA UNA QUIMIOTERAPIA CONTRA EL CANCER, EN PARTICULAR PARA EL TRATAMIENTO DE UNA RESISTENCIA A MULTIPLES FARMACOS.
ES94914200T 1993-04-19 1994-04-13 Derivados de 10,11-metanodibenzosuberano usados como agentes quimiosensibilizantes. Expired - Lifetime ES2121603T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/049,065 US5643909A (en) 1993-04-19 1993-04-19 10,11-Methanodibenzosuberane derivatives

Publications (1)

Publication Number Publication Date
ES2121603T3 true ES2121603T3 (es) 1998-12-01

Family

ID=21957890

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94914200T Expired - Lifetime ES2121603T3 (es) 1993-04-19 1994-04-13 Derivados de 10,11-metanodibenzosuberano usados como agentes quimiosensibilizantes.

Country Status (21)

Country Link
US (5) US5643909A (es)
EP (2) EP0866063A1 (es)
JP (1) JP3020607B2 (es)
KR (1) KR100248591B1 (es)
CN (2) CN1045204C (es)
AT (1) ATE172194T1 (es)
AU (1) AU678470B2 (es)
BR (1) BR9405965A (es)
CA (1) CA2160881C (es)
CZ (1) CZ287273B6 (es)
DE (1) DE69413958T2 (es)
DK (1) DK0695293T3 (es)
ES (1) ES2121603T3 (es)
FI (1) FI111161B (es)
HU (2) HU227824B1 (es)
NO (1) NO313284B1 (es)
NZ (1) NZ265547A (es)
PL (1) PL183375B1 (es)
RU (1) RU2167154C2 (es)
UA (1) UA42720C2 (es)
WO (1) WO1994024107A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6365588B1 (en) 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5661152A (en) * 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
JPH10505348A (ja) 1994-08-31 1998-05-26 イーライ・リリー・アンド・カンパニー 耐性腫瘍の同定および治療方法
US5684013A (en) * 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en) * 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5801175A (en) 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5891872A (en) * 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
CA2258556A1 (en) * 1996-06-17 1997-12-24 Julian Stanley Kroin Drug resistance and multidrug resistance modulators
EP0844244A1 (en) * 1996-11-22 1998-05-27 Eli Lilly And Company Drug resistance and multidrug resistance modulators
US6268500B1 (en) 1997-01-31 2001-07-31 Eli Lilly And Company Separation of 5-nitroquinoline and 8-nitroquinoline
US5776939A (en) * 1997-06-12 1998-07-07 Eli Lilly And Company Drug resistance and multidrug resistance modulators
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
DE60021075T2 (de) 1999-05-19 2006-05-24 Noboru Kaneko Verwendung von 1,4-benzothiazepinderivaten als arzneimittel zur überwindung einer resistenz gegenüber einem arzneimittel gegen krebs
TWI267511B (en) 1999-06-03 2006-12-01 Lilly Co Eli Process for preparing 10,11-methanobenzosuberane derivatives
EP1198462B1 (en) 1999-06-03 2004-09-29 Eli Lilly And Company Process for preparing a 10,11-methanodibenzosuberane derivative
WO2001010387A2 (en) * 1999-08-09 2001-02-15 Vanderbilt University Antiviral therapy use of p-glycoprotein modulators
US6610681B1 (en) * 1999-08-16 2003-08-26 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
WO2002005818A2 (en) * 2000-07-18 2002-01-24 Eli Lilly And Company Novel method of use of multidrug resistance modulators
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
WO2002087581A1 (en) * 2001-04-25 2002-11-07 Eli Lilly And Company Novel salt and crystalline forms of (2r)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
JP2007511519A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 液状投薬形態物におけるトピラメートの制御放出
EP1791520A2 (en) * 2004-08-19 2007-06-06 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
CA2605180A1 (en) * 2005-04-19 2006-10-26 Alza Corporation Controlled delivery dosage form of tramadol and gabapentin
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070009534A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070009533A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
CA2630087A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009535A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
WO2007041079A2 (en) * 2005-09-30 2007-04-12 Alza Corporation Banded controlled release nanoparticle active agent formulation dosage forms and methods
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
MX2011011459A (es) * 2009-04-29 2011-11-18 Rexahn Pharmaceuticals Inc Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US11240349B2 (en) * 2014-12-31 2022-02-01 Ebay Inc. Multimodal content recognition and contextual advertising and content delivery
IL274701B2 (en) 2017-12-01 2024-07-01 Ultragenyx Pharmaceutical Inc Promote drugs, compositions and methods of their use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133925A (en) * 1960-12-22 1964-05-19 Searle & Co Ether derivatives of n-benzhydryl-n'-dihydroxypropylpiperazines and homopiperazines
GB1317034A (en) * 1970-11-06 1973-05-16 Pfizer Ltd 1-2-hydroxy-3-phenoxy- or -phenylthiopropyl-piperazine derivatives
IT1037099B (it) * 1975-01-24 1979-11-10 Erba Carlo Spa N derivati tricilici dell azetidina
US4015003A (en) * 1975-09-26 1977-03-29 E. I. Du Pont De Nemours And Company Antidepressant 1,1a,6,10b-tetrahydrodibenzo[a,e]-cyclopropa-[c]-cyclohepten-6-substituted oximes
JPS5278881A (en) * 1975-12-24 1977-07-02 Sumitomo Chem Co Ltd Synthesis of novel morpholine derivativs
JPS5278882A (en) * 1975-12-24 1977-07-02 Sumitomo Chem Co Ltd Synthesis of novel morpholine derivatives
JPS5278884A (en) * 1975-12-25 1977-07-02 Sumitomo Chem Co Ltd Synthesis of novel morpholine derivatives
JPS52105184A (en) * 1976-02-26 1977-09-03 Sumitomo Chem Co Ltd Novel morpholine derivatives
GB2163150B (en) * 1984-07-19 1988-05-25 Sandoz Ltd 3-aminopropoxyaryl derivatives
JPS6147466A (ja) * 1984-08-10 1986-03-07 Dainippon Pharmaceut Co Ltd アミン誘導体
DE3600390A1 (de) * 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
JPH0278884A (ja) * 1987-11-06 1990-03-19 Sanyo Electric Co Ltd 断熱箱体の内箱
JPH0278881A (ja) * 1988-09-13 1990-03-19 Waaku:Kk 真空冷却装置
JPH0278882A (ja) * 1988-09-14 1990-03-19 Toshiba Corp 冷蔵庫
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
JPH02105184A (ja) * 1988-10-14 1990-04-17 Canon Inc 現像装置
JP2781073B2 (ja) * 1991-02-16 1998-07-30 三井化学株式会社 新規キノリン誘導体及びそれを有効成分として含有する制癌剤効果増強剤
JPH0525168A (ja) * 1991-07-15 1993-02-02 Kyorin Pharmaceut Co Ltd 癌細胞に対する感受性増強剤及びその製造方法
CA2074061A1 (en) * 1991-08-26 1993-02-27 Ivo Monkovic Benzamide multidrug resistance reversing agents
JP3076672B2 (ja) * 1992-06-18 2000-08-14 三井化学株式会社 キノリン誘導体のフマル酸塩
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives

Also Published As

Publication number Publication date
NO313284B1 (no) 2002-09-09
DE69413958D1 (de) 1998-11-19
US5889007A (en) 1999-03-30
CN1119149C (zh) 2003-08-27
UA42720C2 (uk) 2001-11-15
CZ287273B6 (en) 2000-10-11
DE69413958T2 (de) 1999-03-11
HU227824B1 (en) 2012-03-28
US6087365A (en) 2000-07-11
CZ272495A3 (en) 1996-04-17
FI954979A7 (fi) 1995-10-18
NO954161L (no) 1995-12-05
EP0866063A1 (en) 1998-09-23
CA2160881A1 (en) 1994-10-27
HU211682A9 (en) 1995-12-28
RU2167154C2 (ru) 2001-05-20
NZ265547A (en) 1997-03-24
ATE172194T1 (de) 1998-10-15
PL311164A1 (en) 1996-02-05
EP0695293A1 (en) 1996-02-07
WO1994024107A1 (en) 1994-10-27
CA2160881C (en) 2000-12-12
HUT73180A (en) 1996-06-28
PL183375B1 (pl) 2002-06-28
AU678470B2 (en) 1997-05-29
US5874434A (en) 1999-02-23
EP0695293B1 (en) 1998-10-14
US5643909A (en) 1997-07-01
AU6636294A (en) 1994-11-08
BR9405965A (pt) 1996-01-30
CN1045204C (zh) 1999-09-22
DK0695293T3 (da) 1999-06-23
HU9503004D0 (en) 1995-12-28
CN1121346A (zh) 1996-04-24
US5654304A (en) 1997-08-05
NO954161D0 (no) 1995-10-18
CN1235826A (zh) 1999-11-24
FI954979A0 (fi) 1995-10-18
HK1011981A1 (en) 1999-07-23
JP3020607B2 (ja) 2000-03-15
FI111161B (fi) 2003-06-13
KR100248591B1 (ko) 2000-04-01
JPH08509223A (ja) 1996-10-01

Similar Documents

Publication Publication Date Title
ES2118160T3 (es) Compuestos de azol, su produccion y su uso.
ES2002254A4 (es) Nuevos 5-alcoxi-2,4-diamino-alquilbenzenos asi como tintes para el cabello con 5-alcoxi-2,4-diamino-alquil-benzenos.
ES2083941T3 (es) Producto para el teñido oxidativo del cabello a base de 4,5-diamino-pirazoles y derivados de m-fenilen-diamina.
AR034282A1 (es) Derivados de difenilazetidinona, medicamentos que contienen estos compuestos, procedimiento para su preparacion, y su utilizacion para la preparacion de medicamentos
ES2196806T3 (es) Derivados de fenilurea y de feniltiourea.
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
ES470407A1 (es) Procedimiento para la preparacion de un compuesto tetraci- clico
CY1108070T1 (el) Παραγωγα κινολινονης, ως αναστολεις κινασης τυροσινης
AR007280A1 (es) Derivados de sustancia activa, composicion y procedimiento para el tratamiento del cabello
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
ES2123873T3 (es) Pirrolocarbazol.
FI934298A0 (fi) Kristallin tiagabine-hydrokloridmonohydrat, dess framstaellning och dess anvaendning
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES2153019T3 (es) Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR025351A1 (es) Agonistas retinoides selectivos par
UY27324A1 (es) Nuevas sales de napsilato i
ES2156212T3 (es) Derivados de azabicicloheptano n-substituidos como neurolepticos, etc.
ES8603752A1 (es) Procedimiento de preparacion de una composicion tintorea para la coloracion directa de fibras queratinicas
AR013241A1 (es) Derivados del acido aminoetilfenoxiacetico, composicion farmaceutica que incluye a dicho derivado, medicamento para reducir el dolor y promover la eliminacion de calculos en urolitiasis, utilizacion de dicho derivado para la fabricacion de dicha composicion farmaceutica y procedimiento para la fabri
ES2178382T3 (es) Compuestos de benciloxiprodigiosina.
ES2058154T3 (es) Un proceso para la preparacion de nuevos derivados disacaridos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 695293

Country of ref document: ES